TESARO Revenue and Competitors

Boston, MA USA

Location

$457M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • TESARO's estimated annual revenue is currently $17.3M per year.(i)
  • TESARO received $409.0M in venture funding in July 2016.
  • TESARO's estimated revenue per employee is $201,000
  • TESARO's total funding is $457M.

Employee Data

  • TESARO has 86 Employees.(i)
  • TESARO grew their employee count by -14% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M3240%$634MN/A
#2
$47.6M237-4%N/AN/A
#3
$22.3M11152%N/AN/A
#4
$23.9M1198%$113MN/A
#5
$0.3M30%N/AN/A
#6
$11.9M5923%N/AN/A
#7
$1.8M367-4%$538MN/A
#8
$48.6M24221%N/AN/A
#9
$21.4M130-13%$525.5MN/A
#10
$11.6M901%$506.4MN/A
Add Company

TESARO (NASDAQ: TSRO) is a biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. We see new possibilities to responsibly develop and commercialize innovative treatments where others may not. Relationships are vital to the success of our business, and we are committed to being a trusted partner to the cancer community. For more information, please visit www.tesarobio.com.

keywords:Enterprise Software,Health It,Healthcare,Pharmaceuticals

$457M

Total Funding

86

Number of Employees

$17.3M

Revenue (est)

-14%

Employee Growth %

N/A

Valuation

N/A

Accelerator

TESARO News

2022-04-06 - Citi, Tesaro Board, Backers Win $5.1 Billion Glaxo Deal Appeal

Tesaro Inc.'s ex-board, backers at New Enterprise Associates Inc., and financial advisers at Citigroup Inc. secured their win against...

2022-04-06 - Del. Justices Uphold Toss Of Suit Over Tesaro's $5.1B Sale

Tesaro Chairman David M. Mott was a general partner at NEA and led its health care practice, and NEA was preparing to start a new fund in 2019 —...

2022-03-30 - Testing for High-Risk Human Papillomavirus in Lower Genital ...

Consulting or Advisory Role: Genentech/Roche, Immunogen, AstraZeneca, TESARO (Inst), VBL Therapeutics, Merck, Aravive, Eisai, Vavotar Life...

2021-10-13 - GSK tan­goes with pri­vate eq­ui­ty play­ers to ex­plore $54B sale of con­sumer unit in­stead of IPO — re­port

The spin­out of Glax­o­SmithK­line’s con­sumer health unit could re­port­ed­ly take the form of a $54 bil­lion sale to pri­vate eq­ui­ty firms. It would mark a piv­ot from pre­vi­ous plans to turn that group in­to its own list­ed com­pa­ny — one in which cur­rent GSK share­hold­ers can con­tin­ ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.5M8619%N/A
#2
$15.1M86-3%N/A
#3
$8.6M866%N/A
#4
$13.3M86-2%N/A
#5
$14.6M865%N/A

TESARO Funding

DateAmountRoundLead InvestorsReference
2014-01-30$100.0MUndisclosedMultipleArticle
2014-09-30$201.2MUndisclosedCitigroupArticle
2015-03-11$179.7MUndisclosedCitigroupArticle
2016-02-29$155.0MUndisclosedKleiner PerkinsArticle
2016-04-22$50.0MUndisclosedArticle
2016-07-01$345.0MUndisclosedMultipleArticle
2016-07-11$409.0MUndisclosedMultipleArticle